101 7. Strengthened Healthcare Thought Leadership: (a) Advanced IHH’s position as a thought leader by focusing on emerging healthcare areas such as AI, digital transformation, and transplant medicine (b) Aligned efforts across all levels to promote innovation, enhance expertise, and strengthen IHH’s brand identity as a pioneer in valuebased care and medical excellence (c) Initiated knowledge-sharing platforms and symposiums to showcase internal and external expertise, driving collaboration and enhancing visibility within the healthcare sector Review of CQI and Serious Reportable Event (SRE) Framework Group Medical and Quality (MAQ) regularly and systematically assessed and refined all the CQIs and Serious Reportable Events (SREs) every two-yearly through the development of a framework for the following reasons (i) continuous quality improvement (ii) enhanced patient safety (iii) outcome measurement (iv) foster transparency and accountability. Group MAQ does horizon scanning and literature review of internationally reported CQIs and SREs and performs crosswalk analysis using the indicators from countries such as the US, UK, Australia and Singapore. Key considerations are identified to determine if the indicators should be included, retained, revised or retired. Indicators are grouped into care domains or SRE categories in accordance to international healthcare quality framework and standard. The indicator technical manuals are revised to ensure benchmarks and references are up-to-date; standardise terminologies; ensure indicator definitions and measurements are logical and accurately reflect country differences. This process ensures relevancy of indicators that gauge safe and quality care as well as effective risk management and control in our healthcare. In 2024, Group MAQ introduced 2 new indicators, retired 2 current indicators, revised definitions where appropriate and make adjustment to the group targets for all indicators to align with international definitions and benchmarks. This was done in close consultation with business unit MAQs through calls, feedback and pilot phase in Q3 2023 to further refine the technical definitions to ensure smooth transition before full implementation in 2024. The next review exercise will commence in 2025 with full implementation in 2026. The review is also a proactive measure to maintain the relevance of indicators which are crucial steps in our ongoing commitment to delivering the highest standards of patient care and clinical excellence. These actions are meticulously aligned with international definitions and benchmarks, ensuring that the indicators remain reflective of best practices in the healthcare industry. Moreover, the framework improves risk management by adapting to changing standards and provides greater control over the quality of care, thereby fostering a safer and more effective healthcare environment. Regular review of CQI and SRE policies Group MAQ regularly reviews and keeps a running ledger of countries’ policies that address CQIs and prevent SREs on half-yearly basis and provide updates at quality and risk management platform. This process ensures a safer and more controlled healthcare environment through adaptation to evolving standards whereby healthcare standards, guidelines, and regulations are dynamic and subject to change. Regular policy reviews allow IHH to stay abreast of evolving standards related to clinical quality and safety and remain in compliance with regulatory requirements, reducing the risk of non-compliance issues. This proactive approach enables us to address potential issues before they escalate, minimising the impact on patient safety. Additionally, regular policy reviews also facilitate a culture of continuous improvement and alignment with best practices. IHH Clinical Risk Assurance Framework The IHH Board, AC and the RMC provided directives that there was a critical need to enhance the risk identification and management process within IHH. Group MAQ took on the task to improve the risk identification and management process for the Clinical Quality and Patient Safety as the designated risk owner for this risk category. Group MAQ currently monitor this risk through assessment of three key risk indicators on a quarterly basis. However, this is suboptimal as it falls short of addressing the broader spectrum of clinical aspects and evaluating the efficacy of our risk control measures. Beyond the imperative of auditing high clinical risk areas for compliance with standards in 2024, Group MAQ sought to be more proactive to prevent high risk incidents from occurring. To achieve this objective, we developed a new clinical risk assurance framework designed to preemptively prevent high-incidence risks by ensuring the implementation of robust risk controls, outlined as follows: • Identifying high risk scenarios in IHH through data-driven approach • Determining a risk rating (likelihood and severity/impact) • Identifying the risk control owners for each of the risk categories identified • Ensuring controls in place to prevent this risk from occurring • Tracking and monitoring of risk categories, effectiveness of risk controls • Quarterly and annual assessment of how adequately clinical risk has been controlled for reporting to IHH board and attestation Group MAQ initiated the comprehensive identification of clinical risks by leveraging a robust dataset comprising two years of historical incident data from IHH Singapore and IHH Malaysia. Through a meticulous analysis, the top 11 clinical risk categories, their sub-categories, and the corresponding risk owners were identified. It is noteworthy that effective risk controls
RkJQdWJsaXNoZXIy NDgzMzc=